Skip to Content

Generic Vyzulta Availability

Vyzulta is a brand name of latanoprostene bunod ophthalmic, approved by the FDA in the following formulation(s):

VYZULTA (latanoprostene bunod - solution/drops;ophthalmic)

Has a generic version of Vyzulta been approved?

No. There is currently no therapeutically equivalent version of Vyzulta available in the United States.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Vyzulta. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: Generic Drug FAQs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

  • Prostaglandin pharmaceutical compositions
    Patent 6,211,233
    Issued: April 3, 2001
    Inventor(s): Del Soldato; Piero
    Assignee(s): Nicox S.A.

    Compounds of the general formula A--X.sub.1 --NO.sub.2, or their pharmaceutical compositions, wherein A contains a prostaglandin residue, X.sub.1 is a bivalent connecting bridge.

    Patent expiration dates:

    • June 17, 2018
      ✓ 
      Drug substance
      ✓ 
      Drug product
  • Prostaglandin derivatives
    Patent 7,273,946
    Issued: September 25, 2007
    Inventor(s): Ongini; Eninnio & Chiroli; Valerio & Benedini; Francesca & Soldato; Piero Del
    Assignee(s): Nicox S.A.

    Prostaglandin nitroderivatives having improved pharmacological activity and enhanced tolerability are described. They can be employed for the treatment of glaucoma and ocular hypertension.

    Patent expiration dates:

    • October 3, 2025
      ✓ 
      Patent use: REDUCTION OF INTRAOCULAR PRESSURE (IOP) IN PATIENTS WITH OPEN-ANGLE GLAUCOMA OR OCULAR HYPERTENSION
      ✓ 
      Drug substance
      ✓ 
      Drug product
  • Prostaglandin derivatives
    Patent 7,629,345
    Issued: December 8, 2009
    Inventor(s): Ongini; Ennio & Chiroli; Valerio & Benedini; Francesca & Del Soldato; Piero
    Assignee(s): Nicox S.A.

    Prostaglandin nitroderivatives having improved pharmacological activity and enhanced tolerability are described. They can be employed for the treatment of glaucoma and ocular hypertension.

    Patent expiration dates:

    • January 5, 2025
      ✓ 
      Patent use: REDUCTION OF INTRAOCULAR PRESSURE (IOP) IN PATIENTS WITH OPEN-ANGLE GLAUCOMA OR OCULAR HYPERTENSION
      ✓ 
      Drug product
  • Prostaglandin derivatives
    Patent 7,910,767
    Issued: March 22, 2011
    Inventor(s): Ongini; Ennio & Chiroli; Valerio & Benedini; Francesca & Soldato; Piero Del
    Assignee(s): Nicox S.A.

    Prostaglandin nitroderivatives having improved pharmacological activity and enhanced tolerability are described. They can be employed for the treatment of glaucoma and ocular hypertension.

    Patent expiration dates:

    • January 5, 2025
      ✓ 
      Patent use: REDUCTION OF INTRAOCULAR PRESSURE (IOP) IN PATIENTS WITH OPEN-ANGLE GLAUCOMA OR OCULAR HYPERTENSION
      ✓ 
      Drug substance
      ✓ 
      Drug product
  • Prostaglandin derivatives
    Patent 8,058,467
    Issued: November 15, 2011
    Inventor(s): Ongini; Ennio & Chiroli; Valerio & Benedini; Francesca & Soldato; Piero Del
    Assignee(s): Nicox S.A.

    Prostaglandin nitroderivatives having improved pharmacological activity and enhanced tolerability are described. They can be employed for the treatment of glaucoma and ocular hypertension.

    Patent expiration dates:

    • January 5, 2025
      ✓ 
      Patent use: REDUCTION OF INTRAOCULAR PRESSURE (IOP) IN PATIENTS WITH OPEN-ANGLE GLAUCOMA OR OCULAR HYPERTENSION
      ✓ 
      Drug substance
Glossary
TermDefinition
Drug PatentA drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation.
Drug ExclusivityExclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant.
RLDA Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart.
Hide